AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

Sees Potential Beyond Vaccines

 
• By Andrew McConaghie
AstraZeneca
The partners hope VaxEquity's self-ampliftying RNA technology can serve as the basis of therapies as well as vaccines.

More from Business

More from Scrip